<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554943</url>
  </required_header>
  <id_info>
    <org_study_id>CE1740</org_study_id>
    <nct_id>NCT01554943</nct_id>
  </id_info>
  <brief_title>Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients</brief_title>
  <official_title>Late Cardiac Evaluation of the Three Arm Belgian Trial A Phase III Randomized Trial Involving Node-positive Early Breast Cancer Patients With a Long Median Follow-up (~ 15 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Tivoli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Sainte Elisabeth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Jolimont-Lobbes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Réseau Hospitalier Médecine Sociale d'Ath</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de Braine-l'Alleud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Late Cardiac Evaluation of the Three Arm Belgian Trial A phase III randomized trial involving
      node-positive early breast cancer patients with a long median follow-up (~ 15 years)

      OBJECTIFS

      Primary:

      • To compare the incidence of late cardiac events between anthracycline and non-anthracycline
      chemotherapy given to node-positive breast cancer patients in the Belgian three arm
      randomized clinical trial

      Secondary:

        -  To compare the late incidence of cardiac events between higher and lower dose
           anthracycline treated node-positive breast cancer patients;

        -  To compare anthracyclines (higher and lower doses) and non-anthracycline chemotherapy
           for:

        -  left ventricular diastolic function assessed by Echo

        -  exercise capacity assessed by 6-minute walk test (6MWT)

        -  cardiac morphology (myocardial inflammation or injury, fibrosis, LVEF) assessed by MRI

        -  serum cardiac biomarkers (BNP and TNT)

        -  patient-reported cardiac symptoms

        -  patient-reported cardiac symptoms assessed by QOL questionnaires are associated with
           subclinical findings on LVEF assessment

        -  cognitive function, functional autonomy, and psychological distress
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to compare the incidence of cardiac events [(defined
      as asymptomatic systolic dysfunction (LVEF &lt; 50%, asymptomatic NYHA I) or symptomatic heart
      failure NYHA class II-IV either by Echo and/or by clinical exam (LVEF &lt; 50% and heart failure
      symptoms)] between anthracycline and non-anthracycline chemotherapy treated node-positive
      breast cancer patients in a long-term follow-up. We will define a binary status for each
      patient: no cardiac event / one or more cardiac events. Analysis of the primary endpoint will
      involve a comparison of the CMF-treated patients versus the pooled anthracycline treated
      patients (EC and HEC). If a significant difference is detected, all paired comparisons will
      also be performed for the primary endpoint (CMF versus EC, CMF versus HEC, EC versus HEC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late cardiac toxicity</measure>
    <time_frame>Exams will be performed only once, which will take place several years after the completion of chemotherapy (up to 15 years)</time_frame>
    <description>The primary objective of this study is to compare the incidence of cardiac events [(defined as asymptomatic systolic dysfunction (LVEF &lt; 50%, asymptomatic NYHA I) or symptomatic heart failure NYHA class II-IV either by Echo and/or by clinical exam (LVEF &lt; 50% and heart failure symptoms)] between anthracycline and non-anthracycline chemotherapy. Analysis of the primary endpoint will involve a comparison of the CMF-treated patients versus the pooled anthracycline treated patients (EC and HEC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late cardiac and cognitive toxicity</measure>
    <time_frame>Exams will be performed only once, which will take place several years after the completion of chemotherapy (up to 15 years)</time_frame>
    <description>To compare the late incidence of cardiac events between higher and lower dose anthracycline treated node-positive breast cancer patients;
To compare anthracyclines (higher and lower doses) and non-anthracycline chemotherapy for: LVEF assessed by Echo; exercise capacity assessed by 6-minute walk test; cardiac morphology assessed by MRI; serum cardiac biomarkers; patient-reported cardiac symptoms assessed by QOL questionnaires; cognitive function, functional autonomy, and psychological distress</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CMF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adjuvant standard CMF given from 1988 to 1996</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant EC chemotherapy given from 1988 to 1996</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose epirubicin (HEC) given from 1988 to 1996</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cardiac MRI</intervention_name>
    <description>Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy</description>
    <arm_group_label>CMF</arm_group_label>
    <arm_group_label>EC</arm_group_label>
    <arm_group_label>HEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alive, free of any recurrence, Not lost to follow-up

          -  Last workup should be no older than 1 year to exclude relapses. If this is older than
             1 year, a new workup (PE, blood tests and MMG) will be performed prior to the entry in
             this study

          -  Patients previously diagnosed with CHF who are free of recurrence will also be invited
             to participate, if there is no contra-indication

          -  Patients should be able to perform the prescribed assessments

        Exclusion Criteria:

          -  Death

          -  Breast cancer recurrence

          -  Unwilling to perform exams as per protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evandro de Azambuja, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol. 2001 Jun 15;19(12):3103-10.</citation>
    <PMID>11408507</PMID>
  </reference>
  <reference>
    <citation>de Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, Finet C, Ries F, Closon-Dejardin MT, Kerger J, Gobert P, Focan C, Tagnon A, Dolci S, Nogaret JM, di Leo A, Piccart-Gebhart MJ. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. J Clin Oncol. 2009 Feb 10;27(5):720-5. doi: 10.1200/JCO.2008.17.2155. Epub 2008 Dec 22.</citation>
    <PMID>19103732</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMF</keyword>
  <keyword>HEC</keyword>
  <keyword>EC</keyword>
  <keyword>node positive</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

